O'Toole S M, Sekula L K, Rubin R T
Neurosciences Research Center, MCP Hahnemann School of Medicine, Pittsburgh, Pennsylvania, USA.
Biol Psychiatry. 1997 Jul 15;42(2):85-9. doi: 10.1016/S0006-3223(96)00293-4.
To determine the relationship of pretreatment hypothalamic-pituitary-adrenal cortical (HPA) axis measures in major depressives to the occurrence of relapse following discontinuation of successful treatment, we compared pretreatment demographic, clinical, and HPA axis measures in 35 patients with DSM-III-R primary major depression divided into two groups. One group (n = 26) required continuing treatment to hold their symptoms in abeyance, and the other group (n = 9) had been successfully tapered off medication, remained in remission, and had been medication-free for at least 1 month. The major features that differentiated the 26 patients who required continuing medication to abate their symptoms from the 9 patients who were successfully discontinued from treatment were trends toward a longer duration of episode prior to initial study and increased baseline corticotropin (ACTH) 1-39, and significantly higher baseline cortisol and cortisol response to ACTH 1-24, in the former group. These results suggest that measures of HPA axis hyperactivity, along with longer duration of the index depressive episode, may predict the need for continuing medication for patients to remain in remission.
为了确定重度抑郁症患者治疗前下丘脑 - 垂体 - 肾上腺皮质(HPA)轴指标与成功治疗停药后复发的关系,我们比较了35例符合DSM - III - R标准的原发性重度抑郁症患者治疗前的人口统计学、临床和HPA轴指标,这些患者被分为两组。一组(n = 26)需要持续治疗以控制症状,另一组(n = 9)已成功减药,处于缓解期且至少1个月未服药。将需要持续服药以减轻症状的26例患者与成功停药的9例患者区分开来的主要特征是,前一组在初始研究前发作持续时间较长、基线促肾上腺皮质激素(ACTH)1 - 39升高,以及基线皮质醇和皮质醇对ACTH 1 - 24的反应显著更高。这些结果表明,HPA轴功能亢进的指标以及索引抑郁发作持续时间较长,可能预示着患者需要持续服药以维持缓解状态。